In 2016, during the previous congress on Phage Therapy, Prof. Martin Witzenrath, from Charité - Universitätsmedizin Berlin, Germany, was awarded for his scientific contribution regarding the phage therapy and especially about Bacteriophage therapy for lung infections. This year during Florence Congress, Prof. Witzenrath will update the scientific advances on this strategic topic.
Prof. Martin Witzenrath, physician and researcher, dedicates his scientific work to the development of novel therapeutic options for lung diseases, including pneumonia, acute respiratory distress syndrome, pulmonary hypertension and asthma. Using experimental in vitro, ex vivo and in vivo techniques, his group aims at translating novel achievements of basic science into clinical perspectives. One of the current projects aims at providing scientific evidence for the use of bacteriophages produced under GMP conditions against multiresistant gramnegative bacteria. Preclinical evaluation is currently performed, and randomized, double-blind, placebo-controlled clinical studies are planned.
If you would like to know more about Phage Therapy 2016, please click here.